Leo Pharma and MorphoSys Expands Their Existing Collaboration of Antibody-Based Therapies in Dermatology- to Peptide-Derived Therapeutics
Shots:
- Leo Pharma(Leo) will select the targets and MorphoSys will recognize lead molecules using peptide technology platform. Leo Pharma will either develop the lead molecules or use them to design the other drug candidates
- Leo will have exclusive- worldwide rights and take care of the development and commercialization of any drugs developed in dermatology. MorphoSys will have an option to acquire worldwide rights to any drugs developed in the collaboration in the field of oncology
- MorphoSys to receive R&D funding with development- regulatory and commercial milestone payments and royalties on net sales of product by Leo Pharma
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
